Cardiomyopathy and Kidney Function in Agalsidase Beta-Treated Female Fabry Patients: A Pre-Treatment vs. Post-Treatment Analysis

Abstract

Cardiac hypertrophy, progressing during pretreatment follow-up, appeared to stabilize during sustained agalsidase beta treatment. eGFR decline remained within normal ranges. This suggests that treatment may prevent further Fabry-related progression of cardiomyopathy in female patients and maintain normal kidney function.